[Experimental basis fur using D-penicillamine in liver cirrhosis].
The therapeutic action of D-penicillamine (D-PA) in experimental liver cirrhosis was examined comprehensively and compared to that of prednisolone. D-RA primarily depressed fibrillogenesis, preventing the appearance of scar lesions in liver tissue. The drug exerted a beneficial effect on excretory and albumin-synthetizing function of the liver and had a protective action of oxidation function of liver mitochondria and the content of cytochromes. Unlike D-PA, prednisolone primarily reduced the manifestations of auto-immunization. The remainder of the tests have revealed no essential differences in the action of the drugs. The risk of prednisolone overdosage and side effects it produces have been recorded.
D000818:Animals; D002682:Chinchilla; D008099:Liver / Q000503:physiopathology / Q000648:ultrastructure; D008106:Liver Cirrhosis, Experimental / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008854:Microscopy, Electron; D010396:Penicillamine / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use*; D011817:Rabbits
D011239:Prednisolone; D010396:Penicillamine
Eksperimental'noe obosnovanie primeneniia D-penitsillamina pri tsirroze pecheni.